AstraZeneca expands research in heart failure with diabetes drug

29 August 2018

As part of its stated aim to understand more clearly the underlying links between the heart, kidney and pancreas, Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has announced two advances of its heart failure (HF) research program for Forxiga (dapagliflozin), an approved type-2 diabetes drug.

A new Phase III DELIVER trial will evaluate the effects of Forxiga on reducing cardiovascular death or worsening HF in patients with HF and a preserved ejection fraction, a condition where the heart muscle contracts normally but the ventricles do not relax as they should, resulting in a decreased total amount of blood pumped throughout the body.

The other update is the close of enrolment of the Phase III DAPA-HF trial, the first study to assess the potential cardiovascular benefits of a SGLT-2 inhibitor in patients with and without type-2 diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK